










































Evidence-Based Recommendations for Local Antimicrobial
Strategies and Dead Space Management in
Fracture-Related Infection
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Summary: Fracture-related infection (FRI) remains a challenging
complication that imposes a heavy burden on orthopaedic trauma
patients. The surgical management eradicates the local infectious
focus and if necessary facilitates bone healing. Treatment success
is associated with debridement of all dead and poorly vascularized
tissue. However, debridement is often associated with the
formation of a dead space, which provides an ideal environment
for bacteria and is a potential site for recurrent infection. Dead
space management is therefore of critical importance. For this
reason, the use of locally delivered antimicrobials has gained
attention not only for local antimicrobial activity but also for dead
space management. Local antimicrobial therapy has been widely
studied in periprosthetic joint infection, without addressing the
specific problems of FRI. Furthermore, the literature presents
a wide array of methods and guidelines with respect to the use of
local antimicrobials. The present review describes the scientific
evidence related to dead space management with a focus on
the currently available local antimicrobial strategies in the
management of FRI.
Key Words: local antimicrobials, local antibiotics, fracture-related
infection, dead space management, debridement, irrigation, PMMA,
osteomyelitis, ceramics, carriers, fracture, infection
Level of Evidence: Therapeutic Level V. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:18–29)
INTRODUCTION
Fracture-related infection (FRI) remains a challenging
complication. Surgical management is often unavoidable,
particularly for chronic/late onset infections where osteolysis
and biofilm formation are generally present. Successful eradica-
tion of infection requires debridement of affected tissues,
removal of loose implants or foreign bodies, creation of a stable
fracture environment, dead space management, and systemic
antimicrobial therapy. Administration of local antimicrobials, in
addition to systemic therapy, may be beneficial.1,2
The adjunctive application of local antimicrobial agents
in FRI offers the prospect of improved therapeutic efficacy
over that achievable by systemic delivery alone.3–7 This is
expected because the antimicrobial agent is placed directly
within the surgical field and any vascular compromise at
the fracture site or surrounding soft tissues does not limit local
concentrations as it may do for systemically administered
antimicrobials. In addition, with local delivery, the total drug
amount may be reduced, yet the local concentrations exceed
systemic administration. This improves the impact of antimi-
crobial agents, while reducing the risk of systemic toxicity.
Many related studies primarily focused on peripros-
thetic joint infection (PJI), and few investigations have
addressed the specific problem of FRI with different opinions
and practices on the use of local antimicrobials. Indications,
application techniques, dosages, types of antibiotics, elution
properties, and pharmacokinetics are poorly defined in the
clinical setting, leading to a variation in clinical practice.8
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Inappropriate and overuse of antibiotics is becoming an
important issue in orthopaedic trauma surgery.8,9
This review describes the scientific evidence for
currently available local antimicrobial strategies in the
management of FRI.
DEBRIDEMENT, IRRIGATION, AND DEAD
SPACE MANAGEMENT
Debridement remains critical in the treatment of FRI,
and it should include the excision of necrotic and poorly
vascularized (ie, nonbleeding) bone/soft tissue and removal of
loose implants or foreign bodies. Furthermore, multiple tissue
samples should be taken for diagnostic purposes.1,2,10
Debridement is followed by irrigation to further
decrease the bacterial load. Open fracture studies showed
that irrigation should be performed using normal saline at low
pressure to avoid bacterial seeding.11–13 Antimicrobial addi-
tives are not advised.14,15 The optimal amount of irrigation
fluid is unknown, and irrigation should be continued until the
wound is macroscopically clean.
Debridement in FRI often creates a dead space, which is
a poorly perfused defect allowing bacterial proliferation. Fur-
thermore, this environment of low oxygen and pH is ideal for the
development of biofilm and bacterial persistence. Therefore, local
antimicrobial delivery systems are often used as temporary or
definitive strategies for dead space management.16
LOCAL ANTIMICROBIAL STRATEGIES BASED
ON ANTIBIOTICS
Antibiotics Available for Local Use
The chosen antibiotic must provide coverage against
a wide range of pathogens (ie, broad-spectrum antibiotic) or
against a specific pathogen identified by culture17,18; it must be
compatible with and achieve an adequate release from the cho-
sen carrier, and it must have a good toxicity and hypersensitivity
profile, and a low rate of resistance.19 In clinical orthopaedic
practice, gentamicin, tobramycin, vancomycin, and clindamycin
are the most common commercially available formulations for
local antibiotic delivery. They are industrially incorporated into
bone cement, collagen, and other bone void fillers that are avail-
able for clinical use.8 Aside from commercially available prep-
arations, the off-label addition of antibiotics to polymethyl
methacrylate (PMMA) is an option. The mechanical needs of
the construct may have to be considered because an antibiotic
can compromise the strength and setting characteristics of
PMMA. In most FRI cases, antibiotic-impregnated PMMA
beads and spacers are used for dead space management, and
any deterioration of their mechanical properties is not an issue.
However, in large segmental defects of the lower extremity, the
structural integrity of the spacer (in combination with the
osteosynthesis/external fixator) may facilitate weight bearing.
Although local administration of antibiotics is generally
considered safe,20 the potential for systemic toxicity should
not be neglected.21 Also, due consideration should be given to
the effect that antibiotics have on cell viability and osteogenic
activity in the immediate vicinity of the applied material.22,23
Local antibiotics in very high concentrations produce cellular
toxicity and may lead to attenuated fracture healing. This is
a concern given that most local delivery systems release a very
high dose of antibiotics, in some cases, more than 1000 times
the minimal inhibitory concentration (MIC).23,24 However, no
specific cutoff values for local skeletal toxicity exist. Data
from in vitro studies indicate increased toxicity—decreased
proliferative capacity of osteoblasts and chondrocytes23—
with increased antibiotic concentration and exposure time,
which suggests that although higher doses of antibiotic may
be better at controlling infection, they are not benign.
Rathbone et al22 showed in vitro that the antibiotics that
caused the greatest destruction of cell viability and suppres-
sion of osteoblast activity included rifampin, minocycline,
doxycycline, nafcillin, penicillin, ciprofloxacin, colistin meth-
anesulfonate, and gentamicin. More recent, in vivo studies
have demonstrated that the local application of gentamicin,
in standard available doses, does not interfere with fracture/
bone healing.25,26 Amikacin, tobramycin, and vancomycin
were the least cytotoxic until very high concentrations were
used.22 Chu et al27 evaluated the effect of topical vancomycin
on mesenchymal stem cells in vitro. The authors concluded
that there was a dose-dependent cell death with vancomycin
use. These data suggested that more vancomycin is harmful
in vitro, and surgeons should restrict local vancomycin use to
the doses currently reported in the available published studies
(ie, 1–2 g). Also, Naal et al28 demonstrated that clindamycin
levels higher than 500 mg/mL had cytotoxic effects on osteo-
blasts. The authors suggested that the observed effects could
lead to a potential alteration of bone metabolism in vivo.
Fluoroquinolones have been shown to inhibit growth and
extracellular matrix mineralization in osteoblastic cell cul-
ture29 and found to inhibit bone growth in an experimental
fracture model.30 Fluoroquinolones may therefore compro-
mise the clinical course of fracture healing. A review by
Kallala et al31 confirmed the negative in vitro and in vivo
effects of high doses of local antibiotics on bone cell metab-
olism and fracture healing. With this in mind, treating physi-
cians should be careful not to induce local and/or systemic
toxicity. Table 1 gives an overview of local antimicrobials
and the doses that have been reported in the literature.
Discrepancy exists between in vitro and in vivo
antibiotic release, and these data are not interchangeable. A
typical in vitro experiment will allow antibiotics to diffuse
into a large volume of a solution that may be regularly
refreshed. In contrast, in vivo antibiotic release may differ
because the properties of the fluid medium (amount of fluid,
exchange rate) in the vicinity of the material may vary from
the in vitro situation. In vitro data should be considered an
indicator of potential antibiotic release rather than a real
measure of in vivo release.
For PMMA, where the exothermic polymerization
process can result in temperatures exceeding 1008C, thermal
stability is a key factor in determining the suitability of an
antibiotic for incorporation.19 Moreover, any antimicrobial or
carrier should be thermally stable at body temperature for the
duration of release.19 A recent study found that beta-lactam
antibiotics degrade quite rapidly at 378C, whereas excellent
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Gentamicin 0.5 g 1 g Palacos R + G
Gentamicin + vancomycin 0.5 g + 2 g Copal G + V
Gentamicin + clindamycin 1 g + 1 g Copal G + C
Tobramycin 1 g Simplex P
Erythromycin + colistin 0.73 g + 0.24 g Simplex
Customized†‡
Gentamicin 0.4 g 4.8 g 32
Vancomycin 2 g 6 g 32–36
Tobramycin 1.2 g 4.8 g 32,33,37
Gentamicin + vancomycin 0.5 g + 2 g 4.8 g + 4 g‡ 20,38,39
Tobramycin + vancomycin 1.2 g + 1 g 3.6 g + 4 g 40,41
Gentamicin + tobramycin +
vancomycin
0.5 g + 2.4 g + 2 g 42
Gentamicin + clindamycin 0.5–1g + 1g 43
Gentamicin + linezolid 0.5 g + 1 g
Gentamicin + daptomycin 0.5 g + 2 g
Gentamicin + fosfomycin 0.5 g + 1–2 g
Gentamicin + amphotericin B
(liposomal)
0.5 g + 0.2–0.3 g
Gentamicin + amphotericin
B (not liposomal)
0.5 g + 0.2 g–0.8 g
Gentamicin + voriconazol 0.5 g + 0.3–0.6 g
Ceramics
Commercially available
Tobramycin 262 mg 4 pellets/kg§ Osteoset T (calcium sulfate)
Vancomycin + gentamicin 1 g + 240 mg Stimulan 10cc (calcium sulfate)





Gentamicin 175 mg 350 mg Cerament 10 mL (calcium sulfate/
hydroxyapatite)Vancomycin 660 mg 1.32 g
Customized‡
Vancomycin 250 mg 6 g 44 Osteoset (calcium sulfate) (variable
number of batches (25 g) was
used)
Vancomycin 1 g 45 Allomatrix 10 cc (demineralized
bone matrix and calcium sulfate)
Vancomycin + gentamicin 2 g + 240 mg 46 Stimulan 10 cc (calcium sulfate)
Vancomycin + tobramycin + cefazolin 1 g + 1.2 g + 1 g 47 Stimulan (calcium sulfate)
Naked antibiotics
Vancomycin (powder) 0.5 g 6 g¶ 48–50
Tobramycin (liquid) 80 mg/40 mL saline 51,52
Vancomycin + tobramycin (powder) 1 g + 1.2 g 53
Ampicillin (powder) 1 g 54
*General toxicities associated with the use of these antibiotics are reported because reports on side effects of local antibiotic therapy are scarce. All customized dosages reported in this table could not be
associated with systemic toxicity. However, studies on the local management of PJI have reported cases of acute renal failure secondary to the use of antibiotic impregnated cement spacers.21,55–57 Furthermore, the
effect of the antibiotic’s concentration on cell viability and osteogenic activity should be considered.22
†The American Academy of Orthopaedic Surgeons (AAOS) published guidelines for the treatment of PJI using antibiotic-loaded cement spacers. They recommend dosages between 3 and 8 g of antibiotic per
batch of cement. Vacuum mixing is contraindicated because it reduces the elution of the antibiotic.58 However, for the cement to remain stable and to keep its structural integrity, we recommend to add up to 10% of
its weight to the cement batch. Therefore, we would recommend a maximum dose of 4 g per batch (40 g) of PMMA. The integration of ß-lactam antibiotics and carbapenems (ie, meropenem) in PMMA was excluded
from this table because these antibiotics show poor thermal stability and degrade rapidly at a physiologic temperature of 378C.19 Also, fluoroquinolones (ie, ciprofloxacin, levofloxacin), rifampin, tetracyclines (ie,
doxycycline, minocycline, tigecycline), and macrolides (ie, azithromycin) were excluded due to their potential local detrimental effects on cell viability and osteogenic activity, as described in vitro.19,22,29
‡The use of more than 1 batch of local antibiotic carrier has been reported, resulting in a higher local dose, without side effects.20,59
§The package insert of Osteoset T calcium sulfate pellets with tobramycin recommends not to exceed the maximum dosage of 4 pellets/kg for adults with normal renal function. An excess usage may cause
serum levels of tobramycin to be elevated above the recommended maximum. In these cases, neurotoxicity and nephrotoxicity may manifest. If the bone defect size requires a higher number of pellets to be
administered, it is recommended to mix the antibiotic-loaded pellets with standard Osteoset bone graft pellets.
¶Caution should be taken when applying such high doses of vancomycin because clinical evidence on safety is scarce. Only one retrospective study of 981 patients who received topical vancomycin during
spinal surgery reported the use of 6 g vancomycin in rare cases. The average dose of vancomycin was 1.16 g in this study.49 In general, most reported vancomycin dosages range between 0.5 g and 2 g.48,50,60
Depending on the extent of the surgical site that is to be covered, we would recommend to adhere to the upper limit of 2 g.
kMaximum and minimum doses were not always mentioned in the literature.
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long-term stability was observed for aminoglycosides, glyco-
peptides, tetracyclines, and quinolones.19
Delivery of Antibiotics Without Carrier
In daily clinical practice, this is represented by anti-
biotics in aqueous solution or powder form. A systematic
review demonstrated that local administration of antibiotic
(ie, vancomycin) powder significantly decreased infection
rates in spine surgery.48 However, the only randomized con-
trolled trial (RCT) on this topic found no difference in infec-
tion rate when vancomycin powder was used in addition to
systemic prophylaxis compared with systemic prophylaxis
alone.61 Other studies reported an increased rate of Gram-
negative infections following the introduction of vancomycin
powder in the operative bed in spine surgery.49,62 The use of
intrawound antibiotic powder has not been studied exten-
sively in orthopaedic trauma. Few preclinical and clinical
studies report the technique and even a positive outcome,
but comparative studies are lacking.53,63–66 An ongoing mul-
ticenter prospective RCT run by the Major Extremity Trauma
Research Consortium is assessing whether local vancomycin
therapy can reduce infection rates after operative treatment of
fractures at high risk of infection.67
Antibiotics can also be administered in aqueous
solution (eg, tobramycin). These antibiotic solutions have
already been used for many years, and experimental and
clinical data suggest that this method of delivery is effec-
tive.51,68 In a case series, the local injection of aminoglyco-
sides was found to reduce the infection rate in open
fractures.52
Delivering “naked” antibiotics does not require a spe-
cialized carrier, and therefore, the cost is lower. However, an
important drawback to this method is the fact that high local
antibiotic levels cannot be sustained.
To date, the application of antibiotics without any
carrier has not been documented in human clinical trials
focused on the treatment of FRI, and further research is
required to make recommendations.
Delivery of Antibiotics by Carrier
Autograft
Autograft provides a combination of scaffolding and
biologically active cells to enhance healing at fracture non-
union sites. Methods for obtaining autograft and potential
sites for harvest are numerous.69,70 Autograft has been well
studied in its natural state,71 complimenting an induced mem-
brane approach,72–76 or combined with antibiotics.77,78 Auto-
graft exhibits some natural resistance to infection, as
evidenced by the Papineau technique,79,80 where the graft is
applied into open wounds that are left to heal for months
through neoepithelialization. However, an experimental study
revealed that when bone marrow aspirate was injected into
active sites of osteomyelitis, the resulting inflammation cre-
ated significantly more bony destruction.81 This supports the
importance of debridement of all infected, poorly vascular-
ized tissue before grafting.82
Autograft can also be used as a carrier for local
antibiotics. In theory, mixing antimicrobials with autograft
provides the optimal solution of dead space management,
enhanced biology, and infection control and has been used
successfully for second-stage grafting of bone defects.73 As
mentioned earlier, part of the resistance to using antibiotics
with fresh autograft is concern regarding cytotoxic effects on
osteocytes/osteoblasts.
A number of clinical studies have been performed on
antibiotic-loaded autograft. Lindsey et al83 showed that to-
bramycin could be mixed with autograft without negative
effects on healing. A study by Chan et al84 reported the
effects of antibiotic-impregnated cancellous bone grafting
on infection elimination and bone incorporation in patients
with infected tibial nonunions. The authors used different
antibiotics targeted to the infecting organisms that were
found during the initial debridement (ie, first stage). The
results suggested that impregnated antibiotics have no
adverse effects on autogenic cancellous bone graft incorpo-
ration. Furthermore, recurrence rates were lower in the
group that received local antibiotics. In a study on infected
tibial nonunions, vancomycin-impregnated cancellous bone
graft was a safe method, with no recurrence of infection.85
However, the study had a reoperation rate of 28% for “heal-
ing disturbances.”
Because scientific evidence from large clinical series is
lacking and optimal antibiotic doses are currently not avail-
able, the routine combination of local antimicrobials with
autogenic cancellous bone graft is not recommended as the
standard of care.
Allograft
The use of human allograft bone avoids the morbidity
of harvesting autologous bone graft but poses a potential risk
for infection when used in a contaminated site both by
introducing bacteria86 and by serving as a sequestrum for
bacteria in the previously infected site.87 Also, allograft bone
lacks the osteoinductive properties of autograft. For these
reasons, allograft has not found wide application in FRIs
associated with bone defects.
Modification of allograft tissue has allowed it to
become a carrier for antibiotics.88 These modifications
include porphyrin adsorption,89 antibiotic impregnation,90–92
antibiotic tethering,93 and chitosan–heparin coating.94 Studies
show that when mixing bone allografts with antibiotics, their
storage capacity and release profile vastly exceeds that of
PMMA.88
In a series of 45 patients undergoing revision of
infected hip and knee prosthetic replacement with impaction
grafting, femoral head allografts were soaked in an antibiotic
solution and revision surgery was done in one stage,
eradicating infection in 96% of the patients.95 Although pos-
itive results have been published, surgeons should be aware
that after release of the antimicrobial substance, allograft still
functions as a foreign body.
Although the incorporation of antimicrobials in bone
graft (ie, autograft and allograft) has been studied for decades
with promising results, there is currently insufficient infor-
mation available with respect to the optimal carrier (ie,
allograft or autograft), optimal antibiotic, and preferred doses
(ie, local and systemic toxicity profiles).
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Polymethyl Methacrylate
PMMA is a commonly used delivery vehicle for
antibiotic therapy. The most popular drugs used are amino-
glycosides (ie, gentamicin—tobramycin) and vancomy-
cin.96,97 These antibiotics exert a synergistic effect with
superior elution properties when used together.98 Other anti-
microbials can also be used, including daptomycin,99 amika-
cin,100 and voriconazole.101 The amount of antimicrobials
mixed into PMMA significantly varies between studies, spe-
cifically with respect to off-label mixing procedures, yet it is
unclear if the success rate depends on the quantity of drug
used. Table 1 gives an overview of standard available and
recommended doses of antimicrobials mixed with PMMA.
PMMA has been used as an antibiotic carrier for
decades.102 It delivers a high dose of antibiotic and may be
used in spacer or bead form for both prevention and treatment
of FRI.103 PMMA can be used as a spacer (eg, Masquelet
technique), or it can be applied in the shape of beads at the
site of infection.104 The local application of antibiotics to the
intramedullary (IM) canal can be achieved by coating ball-
tipped guide wires or flexible rods with antibiotic cement.
Such coating can be achieved by pumping PMMA into a large
chest tube or using a “hand rolling technique” (Fig. 1). This
IM spacer technique is often used for the 2-stage treatment of
infected long bone nonunions and has shown good
results.105,106
The off-label coating of definitive internal implants,
including plates107 and locked IM nails,96,97,108–110 with
PMMA has also been a treatment option for FRI. These
self-made coated implants can provide an alternative to staged
treatment with external fixation followed by definitive inter-
nal fixation.111 Antibiotic-coated implants must often be cus-
tom molded (handmade) in the operating room using PMMA
and a combination of antibiotics (Fig. 1). The antibiotic-
coated locked IM nail has been used with increasing fre-
quency for internal fixation of long bone fractures40 and in
complex knee and ankle fusion cases.112 Disadvantages to the
use of these implants include controlling the heterogeneity of
the antibiotic distribution in the cement, undulations in the
diameter of the nail coating, and the release profile of the
antibiotics from the PMMA.
The type of PMMA used will also affect the elution
characteristics. When PMMA is more porous, it allows
antibiotics to escape from the cement matrix, more readily
improving antibiotic concentrations.113 Furthermore, the
addition of vancomycin or amphotericin B antibiotic powder
in distilled water before mixing with bone cement improves
antibiotic release.114 Porosity will improve the elution for
bone void PMMA spacers and beads but is not ideal for
coating implants or cement rods where fragmentation com-
plicates cement removal.
The variable antibiotic elution rates of PMMA and the
requirement for removal has led to the investigation of
alternative carriers. A systematic review showed that, despite
the long experience with its use and the theoretical advan-
tages, there are no well-executed, prospective studies inves-
tigating the efficacy of antibiotic-loaded PMMA beads in
treating orthopaedic infections.115 However, studies with
respect to the prevention of FRI describe an improved clinical
outcome when using PMMA beads, especially in open
fractures.103
In addition, van de Belt et al116 evaluated the release
profiles of 6 types of bone cements in vitro and found that the
released antibiotic fell below the detection limit after 1 week
and only 4%–17% of the incorporated antibiotic was released.
In a clinical study by Neut et al,117 the authors retrieved
gentamicin-loaded PMMA beads after revision surgery for
PJIs. Cultures were positive for bacteria on gentamicin-
loaded beads in 90% of the patients. A significant amount
of these strains proved to be gentamicin resistant, which rai-
ses concerns over the development of antibiotic resistance due
to prolonged release at subtherapeutic levels.
Local delivery of antibiotics is not a substitute for
thorough debridement. In the presence of remaining avascular
tissue and foreign bodies, bacteria may remain viable despite
initial high doses of antibiotics. Also, PMMA spacers/beads
are not intended for permanent implantation but are tempo-
rarily used for dead space management and local antibiotic
delivery. During the second-stage procedure, they are
removed, and the dead space is addressed with a reconstruc-
tive procedure (eg, bone grafting).
Ceramics
This review describes 2 types of ceramics that are used
in FRI patients: biodegradable ceramics and bioactive glasses.
Both are biodegradable substances, which raise the possibility
of single-stage surgery with definitive soft tissue closure,
avoiding the need for subsequent surgery for spacer (eg,
PMMA) removal.16
Biodegradable Ceramics
The principle types of biodegradable ceramics available
for antibiotic delivery are based on either calcium sulfate or
calcium phosphate.16 The reported antibiotic elution profiles
of both remain fairly similar, with the delivery of antibiotics
above the MIC for between 3 and 4 weeks.16,118 This elution
profile is superior to that of PMMA. For example, Howlin
et al119 showed that calcium sulfate beads maintained antibi-
otic concentrations above MIC for 39 days compared with
PMMA, which was only effective for 12 days.
The most extensively investigated biodegradable
ceramic in the surgical management of FRI and chronic
osteomyelitis is Osteoset T [Wright Medical, Memphis, TN;
Food and Drug Administration (FDA) approved].120–123 In an
RCT, 30 patients with infected long bones received either
Osteoset T or antibiotic-loaded PMMA beads with no differ-
ence in infection eradication or union.120 However, signifi-
cantly more surgical procedures were needed in the cement
group (15 vs. 7; P = 0.04). In a randomized trial, debridement
alone was statistically less effective than debridement with
implanted calcium sulfate with tobramycin (60% vs. 80%)
in medullary infections.122 In a series of 195 cases of long-
bone infection, including 110 infected fractures, Osteoset T
was an effective antibiotic carrier, with 91% infection eradi-
cation in single-stage surgery.124 However, bone formation
was poor, and posttreatment fractures occurred through the
defect in 4.6% of cases.
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In an attempt to improve the performance of inorganic
ceramics, Cerament (Bonesupport, Lund, Sweden; FDA
approval for an investigational device exemption study) with
gentamicin or vancomycin has been developed. It is a flow-
able, cold curing, biphasic composite containing 60% calcium
sulfate and 40% hydroxyapatite. It forms a paste that can be
injected into bone defects.59 In a series of 100 cases, includ-
ing 71 FRIs, Cerament G eradicated infection in 96%.59 A
comparison of the outcomes for Osteoset T and Cerament G
in the surgical treatment of chronic osteomyelitis showed
fewer wound healing problems in the Cerament G group, with
infection recurrence and refractures being 2 times less likely
compared with those in the Osteoset T group.125
Cerament G can be injected into the IM canal in a fluid
state before nail insertion. The carrier coats the surface of the
nail, potentially protecting it from colonization and delivering
a high local dose of antibiotic. Cerament G has been evaluated
in a series of 12 infected nonunions with single-stage revision
fixation. All 12 were infection free at a minimum of 1 year, and
11 healed with single-stage surgery.126
Bioactive Glass
Bioactive glass, a synthetic silicate material, has been
shown to have antibacterial properties that can allow
osteoconduction and possibly osteostimulation.127 Most data
in FRI is available for the bioactive glass S53P4 (Bioglass;
BonAlive Biomaterials Ltd, Turku, Finland; not FDA
approved). Upon implantation, bioactive glass S53P4 under-
goes chemical degradation, thereby releasing sodium and cal-
cium ions. Eventually, together with an increase in pH, this
leads to the conversion of the glass into a carbonate-
substituted hydroxyapatite-like layer similar to bone.127,128
The intrinsic antibacterial property of bioactive glass S53P4
is due to the ion dissolution process that starts immediately
after the bone substitute has been implanted into the body.129
The ion release at the bioactive glass surface induces an
increase in pH and also an osmotic pressure around the bio-
active glass. These phenomena have shown to kill both plank-
tonic bacteria and bacteria in biofilm in vitro.130 In an in vitro
study, bioactive glass S53P4 was compared to antibiotic-
loaded PMMA, with both showing comparable antibacterial
properties against multidrug-resistant bacteria.131
Clinical studies showed a success rate of approximately
90% in the treatment of chronic osteomyelitis, using bioactive
glass S53P4.129,132 However, Geurts et al133 treated 18 pa-
tients in a low-income country with a success rate of only
38%.
Poly(D,L-Lactide) (PDLLA)
The clinical application of antibiotics through a bio-
degradable implant [Poly(D,L-Lactide) (PDLLA)] coating is
a relatively new development.134 Antibiotic-coated implants
do not necessitate additional removal surgeries or delay
wound closure. The only PDLLA-coated fracture-related
implant that is currently commercially available is the PRO-
tect tibia nail (DepuySynthes; Johnson/Johnson Company,
Inc, New Brunswick, NJ; not FDA approved). It is coated
with a layer of PDLLA impregnated with gentamicin. The
coating releases gentamicin over a period of 2 weeks, with
a burst release in the first days.
Two clinical studies evaluated these gentamicin-coated
tibia nails in acute complex fractures and revision cases. In
both studies, no postoperative infectious complications were
documented.135,136 Antibiotic-PDLLA–coated implants may
be a promising option for the prevention of FRI in open
fracture or revision cases.
Collagen Sponges
Collagen is a natural polymer that can be used for drug
delivery.137 Antibiotic impregnated collagen sponges are not
a new development,138 but clinical studies in the field of FRI
are scarce.139 Initially, these sponges were developed to pre-
vent infections by providing high local gentamicin concen-
trations, but more recently, authors also suggested their use in
the treatment of infection.140 Although previous studies sug-
gested promising results with respect to infection prevention
in open fractures,139 a recent RCT showed that the use of 2
gentamicin-collagen sponges compared with no intervention
did not reduce the 90-day sternal wound infection rate.141
Treatment-related studies are all retrospective and published
at least 2 decades ago, with variable results.138,142,143
Hydrogels
Hydrogels are a newer option for the local delivery of
antibiotic agents. Hydrogels in general consist of a polymer-
ized macromolecule that is hydrated with water (and anti-
biotics) to form easily manageable materials with gel-like
properties. Hydrogels can be injectable, allow for minimally
invasive application, can sustain antibiotic release,144 are bio-
degradable, and thus do not require removal surgery. Hydro-
gels have been studied in more detail in preclinical studies,
showing prophylactic efficacy in rabbit FRI and PJI mod-
els.25,145 Furthermore, these gels have shown to allow normal
bone apposition and fracture healing.25,146
Clinical studies focusing on FRI are scare. In a recent
RCT, 256 patients who were scheduled to receive osteosyn-
thesis for a closed fracture were randomly assigned to an
antibiotic-loaded hydrogel or a control group.147 The authors
concluded that there was a reduced infection rate in the hydro-
gel group, without any detectable adverse events or side
effects.
FIGURE 1. A, Polymethyl methacrylate (PMMA)–coated
humeral nail. The nail was custom molded (handmade) in the
operating room using PMMA and a combination of antibiotics.
B, PMMA spacer for application in the IM canal of the tibia. The
application of PMMA on a rod was achieved using a hand
rolling technique.
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Overall, although hydrogels have the disadvantage of
lacking structural strength and release antimicrobials for
a shorter period compared with biodegradable ceramics, the
advantage is a rapid resorption, thereby leaving no foreign
body for biofilm formation.
NONANTIBIOTIC ANTIMICROBIAL STRATEGIES
Silver
Silver has been used as a disinfectant for many
centuries.148,149 Silver is used in its metallic form as a nano-
particle or in silver-containing polymers and composites.150
For orthopaedic applications, silver has been introduced into
hydroxyapatite and bone cement and as a coating for trauma
devices.151
The toxicity of silver to eukaryotic cells has been one of
the major concerns with respect to its use as an implant
coating or as antimicrobial in a bone void filler.149,152 Despite
this, there are numerous silver-functionalized implants and
wound dressings available clinically,153–156 with few reports
of induced toxicity.157 The development and spread of silver
resistance in FRI pathogens is another concern that could
limit silver-based interventions. In general, resistance to silver
is rare, and to date, there are no reports in Gram-positive
species, which account for a majority of FRI pathogens.
Overall clinical studies demonstrate a trend in reducing
infection with silver-coated central venous catheters, urinary
catheters, and ventilator endotracheal tubes.154–156 Similar pos-
itive results were achieved with a silver-coated megaprosthesis,
which has been used in revision arthroplasty due to infection or
in tumor resection.158 Silver-coated external fixation pins have
also been tested in patients, although a lack of efficacy and
elevated serum silver levels have limited the use of these pins.159
Bacteriophages
Bacteriophages (phages) are viruses that selectively
infect, multiply within, and subsequently lyse bacteria. The
use of phages for the treatment of bacterial infections is not
a novel concept, but it has been applied since the start of the
20th century. With the advent of antibiotics, however, phage
therapy lost ground. Although phages have been applied for
almost a century in eastern Europe, clinical studies are
limited.160–162 Currently, with the increase in multidrug-
resistant strains, phage therapy is regaining interest.163 Clin-
ical and experimental studies on orthopaedic implant-related
infections have shown promising results.164,165 Future
research on this topic, with well-conducted clinical trials, is
important.166,167
CONCLUSIONS
In addition to bony stability and soft tissue cover, the
treatment pathway for FRI is founded on successful debride-
ment and irrigation of bone and soft tissue, in combination
with systemic and local antibiotic administration. This review
described the scientific evidence for dead space management
with a focus on currently available local antimicrobial
strategies in the management of FRI. Key recommendations
are summarized in Table 2.
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